Client Spotlight – Akamara Therapeutics, Inc.

Client Spotlight – Akamara Therapeutics, Inc.

Akamara Therapeutics is a private immunotherapy company seeking to change the way people live by developing innovative B cell therapeutics. Akamara is well positioned to capitalize on important emerging science supporting B cell activation as a therapeutic approach in human cancer. Despite positive impact on survival by approved immuno-oncology agents, many patients still do not benefit, and high unmet patient need remains.

Akamara’s lead program, AT-1965, is a novel small molecule B cell activating cancer immunotherapy. In preclinical models of triple negative breast cancer, AT-1965 shows compelling in vivo tumor regression and the ability to induce an immune memory response. AT-1965 also demonstrates meaningful single-agent, anti-tumor activity in multiple additional in vivo solid tumor models, including melanoma, lung and colorectal cancers.

Akamara recently conducted a successful pre-IND meeting with the U.S. Food and Drug Administration (FDA), with positive feedback supporting the company’s plans to submit an Investigational New Drug (IND) application for AT-1965 in the second half of 2020 and of the clinical strategy and development approach for AT-1965. Akamara expects to initiate clinical development of AT-1965 in a clinically enriched solid tumor population by the end of 2020.

Akamara’s management team has been directly involved in the development of nearly 10 approved pharmaceutical products for the benefit of patients and has the relevant experience to lead AT-1965 into the clinic and beyond. Based in Cambridge, Massachusetts, the company is also supported by premier scientific advisors and backed by leading scientific entrepreneurs.

Akamara is seeking funding to advance AT-1965 through its initial solid tumor clinical trial and to support the growth of the company as a clinical-stage organization.

For more information, contact Susan Graf, CEO at [email protected]akamaratx.com or 908-672-8051.